VRTX · 8-K · 20260707PR296710
Product / Drug Pipeline Progress
VERTEX PHARMACEUTICALS INC / MA · 2026-07-07 · Importance 31 · Surprise 42
PALSONIFY is an FDA- and EMA-approved, once-daily oral therapy for adults with acromegaly and launched in the U.S. in October 2025. Atumelnant is a once-daily oral ACTH receptor antagonist in pivotal Phase 3 development for adults with congenital adrenal hyperplasia (CAH) and in Phase 2/3 development for pediatric patients. Atumelnant has also shown potential in ACTH-dependent Cushing’s syndrome in Phase 2, while additional preclinical programs target thyroid eye disease, Graves’ disease, and hyperparathyroidism. The combined PALSONIFY and atumelnant opportunity is estimated at approximately $5 billion or more in peak annual sales, although the transaction itself is excluded from this topic.
Key facts
- PALSONIFY U.S. launch occurred in October 2025. source
- PALSONIFY demonstrated primary endpoint outcomes of patients with IGF-1 ≤1x ULN in PATHFNDR-1 and PATHFNDR-2 trials. source
- PALSONIFY showed no serious adverse events and 2–4 weeks favorable, manageable tolerability to IGF-1 normalization in most patients per the presentation. source
- Atumelnant is a once-daily oral ACTH receptor antagonist currently in Phase 3 for adults with congenital adrenal hyperplasia (CAH) and Phase 2/3 for pediatrics. source
- Atumelnant in Phase 1/2 data showed rapid lowering of urine free cortisol (UFC) and early indications of potential improvement in symptoms of hypercortisolism and was well tolerated. source
- Atumelnant’s target product profile (TPP) was rated by HCPs as potential future standard of care for CAH, with efficacy cited by 75% of endocrinologists as the top reason to select atumelnant TPP. source
- Atumelnant has demonstrated therapeutic potential in patients with ACTH-dependent Cushing’s syndrome (Phase 2). source
- Atumelnant drove robust androstenedione (A4) reduction, sustained even with glucocorticoids reduced to physiologic levels, according to the presentation. source